Remember meForgot password?
    Log in with Twitter
Press Release

Invokana Lawsuit Plaintiffs Highlight Dangerous Side Effects After FDA Safety Warning reports on two lawsuits which have been filed against Janssen Pharmaceuticals (a division of Johnson & Johnson), regarding alleged potential, harmful side effects linked to their type-2 diabetes drug, Invokana. The drug belongs to a new generation of pharmaceutical diabetes treatment along with several other drugs classed as SGLT2 inhibitors. It is anticipated that those plaintiffs who have filed recent lawsuits will be joined by other persons allegedly adversely affected by usage of the named drug.

An allegation shared by plaintiffs is that using Invokana caused them to develop the serious condition of diabetic ketoacidosis. This is a dangerous and potentially fatal outcome in which the body's bloodstream accumulates a surplus of dangerous acid which disturbs healthy metabolic process.

One of the first lawsuits filed against Invokana manufacturers took place on December 15th, 2015. This complaint was filed under case number 1:15-cv-00636 in the U.S. District Court for the Southern District of Alabama. Details gleaned from this particular litigation state that the plaintiff commenced taking the drug, Invokana in December 2014. It is alleged that there was a sudden and unexpected dangerous development of acute diabetic ketoacidosis. This plaintiff alleges that the drug's manufacturers failed in their duty of care to clearly inform her before commencing the drug of this deadly risk and that they have similarly been negligent with other consumers from all across the nation.

The woman alleges that Inkova manufacturer, Janssen was negligent in not clearly warning patients about the potential adverse side effects of their drug and subsequent serious health risks. She also claims that the company neglected to adequately study possible risks linked to usage of the drug. Upon gaining approval from the U.S. Food and Drug Administration to market the drug as a type-2 diabetes medication, Janssen went on to also market the drug "off-label" as as a type-1 diabetes treatment. "Off-label" marketing is a term used when a drug manufacturer allegedly advertises their drug for uses other than those which have been specifically approved by the FDA.

In the Court of Common Pleas, a Philadelphia plaintiff filed a similar lawsuit alleging similar claims. This complaint is listed under case number 15-12-00653 and was filed on December 10, 2015. The male plaintiff in this case, a male commenced taking Invokana in November 2014. It is alleged that after 3 months of using the drug, he was diagnosed with diabetic ketoacidosis.

Concerns were raised regarding recent adequate safety communication issued by the FDA concerning Invokana ingestion and the subsequent dangerous risk of developing diabetic ketoacidosis. The FDA's warning label system required responsible manufacturer, Janssen Pharmaceuticals to alter the product's current labelling to clearly warn consumers about urinary tract infections potentially leading to a ketoacidotic state.

Diabetic ketoacidosis is a life-threatening condition. This new warning has created an urgency to generate greater public awareness of the possible adverse health risks linked to Invokana. Acute ketoacidosis can suddenly develop within 24-hours. Untreated patients may rapidly slip into comas or even die. The FDA is warning patients taking Invokana to carefully watch for signs and symptoms of impending ketoacidosis which can include fatigue, nausea and vomiting, abdominal pain and breathing difficulty.

For more information about the Invokana lawsuits, or this press release, please contact on 888-997-3792.



Banville Law
165 West End Ave #1h, New York, NY 10023

Latest News
Top News